Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bleumink, G. S.
Right arrow Articles by Ch. Stricker, B. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bleumink, G. S.
Right arrow Articles by Ch. Stricker, B. H.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 1317-1319
© 2001 British Society for Rheumatology

Letters to the Editor

Etanercept-induced subacute cutaneous lupus erythematosus

G. S. Bleumink1,2, E. J. ter Borg3, C. G. Ramselaar4 and B. H. Ch. Stricker1,2,

1 Drug Safety Unit, Inspectorate for Healthcare, The Hague,
2 Pharmacoepidemiology Unit, Department of Epidemiology and Biostatistics, Erasmus Medical Center Rotterdam, Rotterdam,
3 Department of Rheumatology and
4 Department of Dermatology, St Antonius Hospital, Nieuwegein, The Netherlands

SIR, Etanercept (Enbrel®) is a human tumour necrosis factor (TNF) receptor p75 Fc fusion protein which is used for the treatment of active rheumatoid arthritis if the response to disease-modifying anti-rheumatic drugs has proved insufficient. TNF is the product of macrophages and exerts powerful effects on the immune system, including the induction of proinflammatory mediators (e.g. interleukin-1, nitric oxide and prostaglandins), metalloproteinases and adhesion molecules [1]. Etanercept acts as a competitive inhibitor of TNF and prevents binding of TNF to the cell surface TNF-R, thereby reducing the biological activity of TNF [2]. . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch DermatolHome page
N. Usmani and M. Goodfield
Efalizumab in the Treatment of Discoid Lupus Erythematosus
Arch Dermatol, July 1, 2007; 143(7): 873 - 877.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
P Geraminejad, M S Stone, and R D Sontheimer
Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus
Lupus, June 1, 2004; 13(6): 473 - 477.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
A P Cairns, M K J Duncan, A E Hinder, and A J Taggart
New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis
Ann Rheum Dis, November 1, 2002; 61(11): 1031 - 1032.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
F Soliotis, M Glover, and A S M Jawad
Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis
Ann Rheum Dis, September 1, 2002; 61(9): 850 - 851.
[Full Text] [PDF]